Article
Hutchinson-Gilford Progeria paves the way for novel targeted anti-aging therapies.
Med (New York, N.Y.) - 9 Apr 2021
Dreesen Oliver, Kennedy Brian
Abstract excerpt
Hutchinson-Gilford Progeria is an accelerated aging syndrome caused by permanently farnesylated mutant lamin A, termed progerin. Recently, the FDA approved Lonafarnib, a farnesyltransferase inhibitor, to treat progeria, while Koblan and colleagues used novel gene editing methods to target the root cause of this disease by correcting the LMNA mutation.
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.